Neuropeptide Y as a far-reaching neuromediator: From energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 1, 2005, Pages 25-32

  Zoccali, Carmine ^a,b  

^a CNR e Nefrologia   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Atherosclerosis; Bone; Cardiovascular; End stage renal disease; Energy balance; Feeding; Neuropeptide Y; NPY; Obesity

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NEUROPEPTIDE Y; PANCREAS POLYPEPTIDE;

ATHEROSCLEROSIS; BODY MASS; BONE MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; ENERGY BALANCE; FOOD INTAKE; GENE CONTROL; GENE DELETION; GENE OVEREXPRESSION; HUMAN; MEDIATOR; METABOLIC REGULATION; MITOGENESIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRANSGENIC MOUSE; WEIGHT;

ANIMALS; BODY WEIGHT; BONE AND BONES; CARDIOVASCULAR DISEASES; ENERGY METABOLISM; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; NEUROPEPTIDE Y; RATS;

EID: 12144271744     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200501000-00005     Document Type: Review

References (61)

1. de Jong-Brink M, ter MA, Tensen CP. NPY in invertebrates: molecular answers to altered functions during evolution. Peptides 2001; 22:309-315.
2. Kalra SP, Kalra PS. NPY - an endearing journey in search of a neurochemical on/off switch for appetite, sex and reproduction. Peptides 2004; 25:465-471. A well-written general review of main neuropeptide Y actions.
3. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell Mol Life Sci 2003; 60:350-377.
4. von Eggelkraut-Gottanka R, Machova Z, Grouzmann E, Beck-Sickinger AG. Semisynthesis and characterization of the first analogues of pro-neuropeptide y. Chembiochemistry 2003; 4:425-433.
5. Herzog H, Hort YJ, Ball HJ, et al. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 1992; 89:5794-5798.
6. Zukowska Z, Whalsted C, Origin and actions of neuropeptide Y in the cardiovascular system. In: Colmers WF, Whalsted C, editors. The biology of neuropeptide Y and related peptides. Totowa, NJ: Humana Press; 1993. pp. 315-388.
7. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 1998; 75-76:231-238.
8. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83:187-195.
9. Ghersi G, Chen W, Lee EW, Zukowska Z. Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding. Peptides 2001; 22:453-458.
10. Mentlein R, Dahms P, Grandt D, Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993; 49:133-144.
11. Cavadas C, Silva AP, Mosimann F, et al. NPY regulates catecholamine secretion from human adrenal chromaffin cells. J Clin Endocrinol Metab 2001; 86:5956-5963.
12. Morris MJ, Cox HS, Lambert GW, et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension 1997; 29:137-143.
13. Grouzmann E, Comoy E, Bohuon C. Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. J Clin Endocrinol Metab 1989; 68:808-813.
14. Pernow J, Lundberg JM, Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci 1987; 40:47-54.
15. Zoccali C, Mallamaci F, Tripepi G, et al. Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. J Am Soc Nephrol 2003; 14:2611-2617. The first study associating high neuropeptide Y with cardiovascular mortality in a chronic renal disease.
16. Odar-Cederlof I, Ericsson F, Theodorsson E, Kjellstrand CM. Neuropeptide-Y and atrial natriuretic peptide as prognostic markers in patients on hemodialysis. ASAIO J 2003; 49:74-80.
17. Medeiros MS, Turner AJ. Metabolism and functions of neuropeptide Y. Neurochem Res 1996; 21:1125-1132.
18. Kallio J, Pesonen U, Karvonen MK, et al. Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY. J Clin Endocrinol Metab 2001; 86:5348-5352.
19. Kallio J, Pesonen U, Jaakkola U, et al. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J Clin Endocrinol Metab 2003; 88:3278-3283. An accurate chronobiological report testing the sympathoadrenal effects of a common polymorphism in the neuropeptide Y gene.
20. Kallio J, Pesonen U, Kaipio K, et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 2001; 15:1242-1244.
21. Michalkiewicz M, Michalkiewicz T, Kreulen DL, McDougall SJ. Increased blood pressure responses in neuropeptide Y transgenic rats. Am J Physiol Regul Integr Comp Physiol 2001; 281:R417-R426.
22. Michalkiewicz M, Knestaut KM, Bytchkova EY, Michalkiewicz T. Hypotension and reduced catecholamines in neuropeptide Y transgenic rats. Hypertension 2003; 41:1056-1062. Transgenic mice overexpressing neuropeptide Y display an unsuspected phenotype.
23. Tsuda K, Tsuda S, Goldstein M, et al. Modulation of noradrenergic transmission by neuropeptide Y and presynaptic alpha 2-adrenergic receptors in the hypothalamus of spontaneously hypertensive rats. Jpn Heart J 1992; 33:229-238.
24. Kalra SP, Kalra PS. Neuropeptide Y: a physiological orexigen modulated by the feedback action of ghrelin and leptin. Endocrine 2003; 22:49-56.
25. Druce M, Bloom SR. Central regulators of food intake. Curr Opin Clin Nutr Metab Care 2003; 6:361-367.
26. Erickson JC, Ahima RS, Hollopeter G, et al. Endocrine function of neuropeptide Y knockout mice. Regul Pept 1997; 70:199-202.
27. Kaga T, Inui A, Okita M, et al. Modest overexpression of neuropeptide Y in the brain leads to obesity after high-sucrose feeding. Diabetes 2001; 50:1206-1210.
28. Pedrazzini T, Seydoux J. Neuropeptide Y Y1 receptor-deficient mice. Generation and characterization. Methods Mol Biol 2000; 153:91-100.
29. Naveilhan P, Hassani H, Canals JM, et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 1999; 5:1188-1193.
30. Sainsbury A, Schwarzer C, Couzens M, et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci USA 2002; 99:8938-8943.
31. Naveilhan P, Hassani H, Canals JM, et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 1999; 5:1188-1193.
32. Naveilhan P, Svensson L, Nystrom S, et al. Attenuation of hypercholesterolemia and hyperglycemia in ob/ob mice by NPY Y2 receptor ablation. Peptides 2002; 23:1087-1091.
33. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998; 4:718-721.
34. Pedrazzini T, Seydoux J, Kunstner P, et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 1998; 4:722-726.
35. Carling D. The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 2004; 29:18-24.
36. Cho YR, Kim CW. Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochem Biophys Res Commun 2004; 314:773-780. Neuropeptide Y inhibits β-cell replication and glucose-stimulated insulin release.
37. Yuzuriha H, Inui A, Goto K, et al. Intracerebroventricular administration of NPY stimulates resistin gene expression in mice. Int J Mol Med 2003; 11:675-676.
38. Bray MS, Boerwinkle E, Hanis CL. Linkage analysis of candidate obesity genes among the Mexican-American population of Starr County, Texas. Genet Epidemiol 1999; 16:397-411.
39. Chagnon YC, Borecki IB, Perusse L, et al. Genome-wide search for genes related to the fat-free body mass in the Quebec family study. Metabolism 2000; 49:203-207.
40. Heijmans BT, Beem AL, Willemsen G, et al. Further evidence for a QTL influencing body mass index on chromosome 7p from a genome-wide scan in Dutch families. Twin Res 2004; 7:192-196.
41. Morris MJ, Russell AE, Kapoor V, et al. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst 1986; 17:143-149.
42. Li MD, Parker SL, Kane JK. Regulation of feeding-associated peptides and receptors by nicotine. Mol Neurobiol 2000; 22:143-165.
43. Gullestad L, Bjuro T, Aaberge L, et al. The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris. Eur Heart J 2003; 24:1120-1127. Y1 receptor antagonism reduces the blood-pressure response to exercise but does not affect exercise-induced cardiac ischemia.
44. Gullestad L, Aass H, Ross H, et al. Neuropeptide Y receptor 1 (NPY-Y1) expression in human heart failure and heart transplantation. J Auton Nerv Syst 1998; 70:84-91.
45. Karvonen MK, Valkonen VP, Lakka TA, et al. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001; 159:145-151.
46. Li L, Lee EW, Ji H, Zukowska Z. Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. Arterioscler Thromb Vasc Biol 2003; 23:1204-1210. A very intriguing study showing that neuropeptide Y is strongly implicated in artery occlusion after balloon angioplasty in the rat.
47. Lee EW, Michalkiewicz M, Kitlinska J, et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003; 111:1853-1862. A fundamental paper unravelling the effects of neuropeptide Y on neoangiogenesis.
48. Karvonen MK, Pesonen U, Koulu M, et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998; 4:1434-1437.
49. Karvonen MK, Koulu M, Pesonen U, et al. Leucine 7 to praline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool aged children. J Clin Endocrinol Metab 2000; 85:1455-1460.
50. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2000; 108:235-236.
51. Zoccali C, Mallamaci F, Tripepi G, et al. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. J Hypertens 2003; 21:1355-1362. The first study associating neuropeptide Y with left-ventricular hypertrophy in a chronic human disease.
52. Kuch-Wocial A, Slubowska K, Kostrubiec M, et al. Plasma neuropeptide Y immunoreactivity influences left ventricular mass in pheochromocytoma. Clin Chim Acta 2004; 345:43-47.
53. Jarvisalo MJ, Jartti L, Karvonen MK, et al. Enhanced endothelium- dependent vasodilation in subjects with Proline7 substitution in the signal peptide of neuropeptide Y. Atherosclerosis 2003; 167:319-326. Individuals with a common polymorphism in the neuropeptide Y gene show an enhanced-flow-mediated vasodilatory response.
54. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-1923.
55. Wallerstedt SM, Skrtic S, Eriksson AL, et al. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 2004; 22:1277-1281.
56. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002; 109:915-921.
57. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100:197-207.
58. Bjurholm A, Kreicbergs A, Terenius L, et al. Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J Auton Nerv Syst 1988; 25:119-125.
59. Pham T, Lafforgue P. Reflex sympathetic dystrophy syndrome and neuromediators. Joint Bone Spine 2003; 70:12-17.
60. Schwarz H, Villiger PM, von KJ, Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol 1994; 51:53-61.
61. Naveilhan P, Hassani H, Lucas G, et al. Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature 2001; 409:513-517.